American Association for Cancer Research
15357163mct140030-sup-125552_2_supp_2682931_ncq784.pdf (1.04 MB)

Supplemental Fig 1,2,3 from Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer

Download (1.04 MB)
journal contribution
posted on 2023-04-03, 14:20 authored by Melissa R. Junttila, Vidusha Devasthali, Jason H. Cheng, Joseph Castillo, Ciara Metcalfe, Anne C. Clermont, Douglas Den Otter, Emily Chan, Hani Bou-Reslan, Tim Cao, William Forrest, Michelle A. Nannini, Dorothy French, Richard Carano, Mark Merchant, Klaus P. Hoeflich, Mallika Singh

Supplemental Fig 1,2,3. Tumor growth rates, overall survival and single agent GDC-0973 in vitro response



Activating mutations in the KRAS oncogene occur in approximately 90% of pancreatic cancers, resulting in aberrant activation of the MAPK and the PI3K pathways, driving malignant progression. Significant efforts to develop targeted inhibitors of nodes within these pathways are underway and several are currently in clinical trials for patients with KRAS-mutant tumors, including patients with pancreatic cancer. To model MEK and PI3K inhibition in late-stage pancreatic cancer, we conducted preclinical trials with a mutant Kras-driven genetically engineered mouse model that faithfully recapitulates human pancreatic ductal adenocarcinoma development. Treatment of advanced disease with either a MEK (GDC-0973) or PI3K inhibitor (GDC-0941) alone showed modest tumor growth inhibition and did not significantly enhance overall survival. However, combination of the two agents resulted in a significant survival advantage as compared with control tumor-bearing mice. To model the clinical scenario, we also evaluated the combination of these targeted agents with gemcitabine, the current standard-of-care chemotherapy for pancreatic cancer. The addition of MEK or PI3K inhibition to gemcitabine, or the triple combination regimen, incrementally enhanced overall survival as compared with gemcitabine alone. These results are reminiscent of the survival advantage conferred in this model and in patients by the combination of gemcitabine and erlotinib, an approved therapeutic regimen for advanced nonresectable pancreatic cancer. Taken together, these data indicate that inhibition of MEK and PI3K alone or in combination with chemotherapy do not confer a dramatic improvement as compared with currently available therapies for patients with pancreatic cancer. Mol Cancer Ther; 14(1); 40–47. ©2014 AACR.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager